Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
about
Pitavastatin in cardiometabolic disease: therapeutic profileHaptoglobin binds the antiatherogenic protein apolipoprotein E - impairment of apolipoprotein E stimulation of both lecithin:cholesterol acyltransferase activity and cholesterol uptake by hepatocytesDysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and LipidomicsHDL particle number and size as predictors of cardiovascular diseaseHDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applicationsAdvances in the Study of the Antiatherogenic Function and Novel Therapies for HDLNew insights into the determination of HDL structure by apolipoproteins: Thematic review series: high density lipoprotein structure, function, and metabolismResidual macrovascular risk in 2013: what have we learned?Statins in cardiometabolic disease: what makes pitavastatin different?Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemiaSequence conservation of apolipoprotein A-I affords novel insights into HDL structure-functionNutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndromeSphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protectionRole of lipids in spheroidal high density lipoproteinsHDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approachAn in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathwayAPOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmidsIn vivo administration of BL-3050: highly stable engineered PON1-HDL complexesMass spectrometric determination of apolipoprotein molecular stoichiometry in reconstituted high density lipoprotein particles.Saikosaponins induced hepatotoxicity in mice via lipid metabolism dysregulation and oxidative stress: a proteomic studyCholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Triglycerides and cardiovascular risk.Type 2 Diabetes in Young Females Results in Increased Serum Amyloid A and Changes to Features of High Density Lipoproteins in Both HDL2 and HDL3.Speciated human high-density lipoprotein protein proximity profilesProteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function.Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010.Evidence for low high-density lipoprotein cholesterol levels in Australian indigenous peoples: a systematic review.Human longevity is associated with regular sleep patterns, maintenance of slow wave sleep, and favorable lipid profile.The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosisNew developments in selective cholesteryl ester uptake.Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteinsOxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol exportImpact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Multimarker screening of oxidative stress in aging.Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis.Quantitative comparison of lipoprotein fractions derived from human plasma and serum by liquid chromatography-tandem mass spectrometry.
P2860
Q21246037-6B517556-CA77-46AF-BB0A-41416BE7EE6FQ24316403-AEE57D66-0727-4299-9983-E3B368228AB2Q26774903-AB326996-82B4-4AAA-B9D4-F9A50EF5F7F6Q26779287-E3DAC7B4-030A-425A-9164-52D2BA7A96D0Q26779667-1720767A-5907-4D57-BB54-A9F0234FF1E2Q26801507-23F85DA2-20F1-4F00-92AE-5F3589AA4647Q26851804-3B2D36DC-8C2A-4A35-AB74-3A30372B222BQ26996039-295CA0E9-3F81-4E3E-8F93-FCD702B5355DQ27010638-AE30055B-7C1A-4267-B2B6-151EE9AC1BDFQ27013494-9FACD4A5-360E-4387-9B8D-0D04A3BA2A1FQ27690671-0F5FC0B2-ACC1-447B-A5A8-41C740513E98Q28079661-4ADDB6ED-3B5D-4E15-839F-EF1D8A8C725EQ28235893-8BC56E52-36B0-4049-AF70-3E853E7DD334Q28475955-A0C7DB23-219F-41E1-B1A3-574FD81CE523Q28481613-EDA3387B-92EF-48BF-9D3B-9D5B3597B680Q28540807-5D5F6797-E16A-479E-8BF1-2A1124F9B94DQ30279056-692363E2-A155-4C1B-B7CA-EE88566C484CQ30380038-3278A7FB-9EB5-43B7-B083-FCB5F76DCCEDQ30891417-0D66F9ED-F87D-4033-A823-9CD850B391FFQ33403980-F12BB902-4904-4393-8AB5-ECDFAA6E7000Q33576349-8F154487-F29A-4EBD-9550-30D152ABD054Q33590777-15B654CC-4407-484D-A151-FD1F0DBAF7BCQ33654016-18598189-9A0D-41CD-84F6-1006CE48F801Q33742998-426D57F2-1EDE-4DF1-A9CA-BD5163C132E3Q33745525-D514D061-9452-4505-A264-460067B717F9Q33752486-2817DF37-82FC-4C45-AF3A-8AA7AD1DB2BEQ33789181-5F1FB86E-6A78-44C0-B5FA-23D03B18A612Q33792573-6A1EADFC-7F98-48E2-85B1-9411363307C1Q33795113-4ADD777F-38E8-41B4-BA2F-F886CF6E2D70Q33837099-A1487AA9-2645-4AD2-91B8-D7728E95D815Q33863769-CDB8F199-C02B-41DE-ADF5-13191A1E5234Q33894679-BBC969A1-6DD1-41CE-B719-C4C677789409Q33897950-E4F45619-83BC-4CEE-B9FE-302C541564DEQ33902023-3637EC63-A0C4-435F-B1F4-B5B66D1F7F1DQ33940875-8F799E44-F329-49B4-AB8E-20B735CC957AQ33972551-2F84A5E2-7DF8-419C-A3A0-E1ECA5C9A6C4Q33993233-91FE09BE-071A-4259-9424-E04D3DBAEC56Q34014251-D38CF0E5-F55D-4AA9-934C-BE45F1986499Q34037325-803F6B8B-A62F-47E9-95C8-BA5F9B7FA339Q34053599-10327C57-47E7-4062-8E50-DB49807F7493
P2860
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Functionally defective high-de ...... ammation, and atherosclerosis.
@ast
Functionally defective high-de ...... ammation, and atherosclerosis.
@en
type
label
Functionally defective high-de ...... ammation, and atherosclerosis.
@ast
Functionally defective high-de ...... ammation, and atherosclerosis.
@en
prefLabel
Functionally defective high-de ...... ammation, and atherosclerosis.
@ast
Functionally defective high-de ...... ammation, and atherosclerosis.
@en
P921
P356
P1476
Functionally defective high-de ...... ammation, and atherosclerosis.
@en
P2093
Anatol Kontush
M John Chapman
P304
P356
10.1124/PR.58.3.1
P577
2006-09-01T00:00:00Z